Stock PBYI PUMA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.02 USD +2.87% Intraday chart for Puma Biotechnology, Inc. +0.20% +15.94%
Mar. 20 Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise MT
Mar. 20 Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer CI

Evolution of the average Target Price on Puma Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

98d8.Q5OBMc4l6vHiVYkudOV4dQZCxrn4_21aoli9jRwIm5E.NcDTX51fp5yzAPscJIAZJUMaoYyVuQk_9xTc1XFG_fwN_dlyj0uYx5Ia5g~ab0f1d5ef31718b6271098830634f8f6

Analyst Recommendations on Puma Biotechnology, Inc.

HC Wainwright Lowers Price Target on Puma Biotechnology Inc to $8 From $12, Reiterates Buy Rating MT
PUMA BIOTECHNOLOGY : Citigroup Upgrades Puma Biotechnology to Buy From Neutral, Price Target at $11 MT
PUMA BIOTECHNOLOGY : RBC Cuts PT on Puma Biotechnology to $6 From $13, Citing Nerlynx 2021 Sales Estimates; Sector Perform-Speculative Risk Rating Kept MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.02 USD
Average target price
4.333 USD
Spread / Average Target
-13.68%
High Price Target
7 USD
Spread / Highest target
+39.44%
Low Price Target
2 USD
Spread / Lowest Target
-60.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Puma Biotechnology, Inc.

HC Wainwright
Citigroup
RBC Capital Markets

Ratings for Puma Biotechnology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PBYI Stock
  4. Consensus Puma Biotechnology, Inc.